Diego Albrecht

897 total citations
17 papers, 715 citations indexed

About

Diego Albrecht is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Diego Albrecht has authored 17 papers receiving a total of 715 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cardiology and Cardiovascular Medicine, 7 papers in Endocrinology, Diabetes and Metabolism and 5 papers in Molecular Biology. Recurrent topics in Diego Albrecht's work include Heart Failure Treatment and Management (8 papers), Hormonal Regulation and Hypertension (6 papers) and Receptor Mechanisms and Signaling (5 papers). Diego Albrecht is often cited by papers focused on Heart Failure Treatment and Management (8 papers), Hormonal Regulation and Hypertension (6 papers) and Receptor Mechanisms and Signaling (5 papers). Diego Albrecht collaborates with scholars based in Switzerland, India and Germany. Diego Albrecht's co-authors include S. Dejager, Anja Schweizer, Michelle A. Baron, Vivian Fonseca, Thomas Langenickel, Parasar Pal, Ellen E. Blaak, Surya Ayalasomayajula, Rudi Stinkens and Gijs H. Goossens and has published in prestigious journals such as Circulation, Scientific Reports and Hypertension.

In The Last Decade

Diego Albrecht

16 papers receiving 698 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Diego Albrecht Switzerland 9 424 333 177 157 102 17 715
Kazuhito Shiosakai Japan 15 133 0.3× 151 0.5× 107 0.6× 81 0.5× 81 0.8× 58 544
Melissa Magwire United States 8 547 1.3× 179 0.5× 166 0.9× 156 1.0× 14 0.1× 21 672
Atheline Major‐Pedersen Denmark 14 271 0.6× 318 1.0× 110 0.6× 166 1.1× 31 0.3× 23 635
Guangyao Wang China 11 155 0.4× 270 0.8× 144 0.8× 75 0.5× 35 0.3× 16 586
TERUHISA UMEDA Japan 15 270 0.6× 136 0.4× 178 1.0× 55 0.4× 37 0.4× 58 607
Martin P. Bedigian United States 9 353 0.8× 480 1.4× 55 0.3× 97 0.6× 21 0.2× 15 680
T. Fasanella D'amore United States 10 118 0.3× 223 0.7× 113 0.6× 115 0.7× 20 0.2× 11 466
Noriko Ban Japan 17 188 0.4× 568 1.7× 282 1.6× 113 0.7× 14 0.1× 24 848
Uwe Hehnke Germany 11 297 0.7× 57 0.2× 123 0.7× 122 0.8× 47 0.5× 23 438
Jwari Ahn United States 10 166 0.4× 332 1.0× 95 0.5× 82 0.5× 13 0.1× 10 534

Countries citing papers authored by Diego Albrecht

Since Specialization
Citations

This map shows the geographic impact of Diego Albrecht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diego Albrecht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diego Albrecht more than expected).

Fields of papers citing papers by Diego Albrecht

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diego Albrecht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diego Albrecht. The network helps show where Diego Albrecht may publish in the future.

Co-authorship network of co-authors of Diego Albrecht

This figure shows the co-authorship network connecting the top 25 collaborators of Diego Albrecht. A scholar is included among the top collaborators of Diego Albrecht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diego Albrecht. Diego Albrecht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Stinkens, Rudi, Birgitta W. van der Kolk, Jens Jordan, et al.. (2018). The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients. Scientific Reports. 8(1). 3933–3933. 8 indexed citations
2.
Schmieder, Roland E., Frank Wagner, Michael Mayr, et al.. (2017). The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. European Heart Journal. 38(44). 3308–3317. 116 indexed citations
3.
Engeli, Stefan, Rudi Stinkens, Tim Heise, et al.. (2017). Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension. Hypertension. 71(1). 70–77. 31 indexed citations
4.
Ayalasomayajula, Surya, Thomas Langenickel, Pierre J. Jordaan, et al.. (2016). Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor. European Journal of Clinical Pharmacology. 72(9). 1065–1073. 27 indexed citations
5.
Kotovskaya, Yu. V., О. В. Аверков, Е.П. Павликова, et al.. (2016). Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction. Cardiovascular Therapeutics. 34(4). 191–198. 66 indexed citations
6.
Jordan, Jens, Rudi Stinkens, Thomas Jax, et al.. (2016). Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension. Clinical Pharmacology & Therapeutics. 101(2). 254–263. 89 indexed citations
7.
Flarakos, Jimmy, Qusai Y. Al–Share, Priya Chandra, et al.. (2016). Disposition and metabolism of [14C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects. Xenobiotica. 46(11). 986–1000. 27 indexed citations
8.
Ayalasomayajula, Surya, Thomas Langenickel, Priya Chandra, et al.. (2016). Effect of food on the oral bioavailability of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics. 54(12). 1012–1018. 8 indexed citations
9.
Ayalasomayajula, Surya, Pierre J. Jordaan, Parasar Pal, et al.. (2013). Abstract 449: Assessment of Pharmacokinetic Drug Interaction Between LCZ696 and Digoxin. Hypertension. 62(suppl_1). 4 indexed citations
10.
Ayalasomayajula, Surya, Pierre J. Jordaan, Parasar Pal, et al.. (2013). Abstract 448: Assessment of Drug Interaction Potential Between LCZ696 and Warfarin. Hypertension. 62(suppl_1). 3 indexed citations
11.
Kobalava, Zhanna, Pierre J. Jordaan, Yu. V. Kotovskaya, et al.. (2013). Short-term treatment with LCZ696 in patients with stable chronic heart failure: effect on biomarkers. European Heart Journal. 34(suppl 1). P5716–P5716.
12.
Khadzhynov, Dmytro, Torsten Slowinski, Ina Lieker, et al.. (2012). Pharmacokinetics of Aliskiren in Patients with End-Stage Renal Disease Undergoing Haemodialysis. Clinical Pharmacokinetics. 51(10). 661–669. 3 indexed citations
13.
Kobalava, Zhanna, О. В. Аверков, I. Meray, et al.. (2011). Natriuretic peptide inhibition in the presence of angioten-sin receptor blockade following short-term treatment with LCZ 696 in heart failure patients: effect on ANP, BNP, NT-proBNP and cGMP. 32. 784–785. 6 indexed citations
14.
Kobalava, Zhanna, et al.. (2010). Abstract 19378: First Experience with Concomitant AT1 and Neprilysin (NEP 24.11) Inhibition with LCZ696 in Patients with Chronic Heart Failure. Circulation. 122. 4 indexed citations
15.
Fonseca, Vivian, et al.. (2007). Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 50(6). 1148–1155. 314 indexed citations
16.
Albrecht, Diego, et al.. (1997). Chronische Rechtsherzbelastung nach Implantation eines Kavasperrfilters. DMW - Deutsche Medizinische Wochenschrift. 122(46). 1415–1418. 8 indexed citations
17.
Albrecht, Diego. (1968). [Aescin for the treatment of edema in urology].. PubMed. 6(6). 345–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazuhito Shiosakai Breakdown of academic impact, for papers by Melissa Magwire Breakdown of academic impact, for papers by Atheline Major‐Pedersen Breakdown of academic impact, for papers by Guangyao Wang Breakdown of academic impact, for papers by TERUHISA UMEDA Breakdown of academic impact, for papers by Martin P. Bedigian Breakdown of academic impact, for papers by T. Fasanella D'amore Breakdown of academic impact, for papers by Noriko Ban Breakdown of academic impact, for papers by Uwe Hehnke Breakdown of academic impact, for papers by Jwari Ahn
Rankless by CCL
2026